Actively Recruiting
Cannabidiol for Reducing Drinking in Alcohol Use Disorder
Led by Hôpital le Vinatier · Updated on 2025-02-27
76
Participants Needed
1
Research Sites
113 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The non-psychotomimetic cannabis compound cannabidiol (CBD) has been found effective for reducing alcohol drinking in mice. Moreover, other experimental studies have found that CBD reduced alcohol-induced steatosis in the liver, and reduced alcohol-related injury in the brain. Despite these promising results from animal data, no human study has been conducted yet in alcohol use disorder (AUD).
CONDITIONS
Official Title
Cannabidiol for Reducing Drinking in Alcohol Use Disorder
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18 to 65 years
- Fluent in French
- Read the information procedure and signed informed consent
- Affiliated with health insurance
- Meet DSM-5 criteria for Alcohol Use Disorder (all stages)
- Average drinking of at least 12 standard drinks per day over the month before inclusion (total of 336 standard drinks in 28 days)
You will not qualify if you...
- Abstinent for at least one day during the month before inclusion
- Liver cirrhosis classified as Child-Pugh B or C
- Diagnosis of schizophrenia, schizoaffective disorder, or bipolar disorder
- Current suicidality or lifelong history of suicide attempts
- History or current other substance use disorder (except alcohol or nicotine)
- Use of cannabis or cannabinoids within 60 days before screening
- Liver enzyme elevations above 3 times normal and bilirubin above 2 times normal
- Impaired medical condition as judged by investigator
- Pregnancy, breastfeeding, or insufficient contraception
- Diagnosis of cancer, HIV, pulmonary arterial hypertension, epilepsy, or certain drug interactions
- History of stroke, cardiac arrhythmias, or myocardial infarction
- Use of certain AUD medications within 30 days prior to screening
- MRI contraindications such as pacemaker or cochlear implant
- Known allergy to cannabidiol or excipients
- Under legal guardianship or curatorship
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Centre Hospitalier Le Vinatier
Bron, Auvergne-Rhône-Alpes, France, 69678 cedex
Actively Recruiting
Research Team
F
Florelle BERTRAND
CONTACT
V
Véronique VIAL
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here